



## TetraGraph Exhibition and Poster presentation at The International Anesthesia Research Society's (IARS) 2018 Annual Meeting, Chicago, Illinois, April 28-May 1

**News: Uppsala, May 4, 2018.** The meeting addresses cutting-edge topics in all anesthesia subspecialties and looks to the future of anesthesia. More than 1,000 of the world's leading minds in anesthesia education and research attends the meeting.



TetraGraph is a unique, EMG-based portable device for quantitative monitoring of neuromuscular function. It's a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician reduce the incidence of residual block. Senzime held demonstrations of the TetraGraph during the conference, with a great interest from clinicians to learn more about its benefits and possibilities.



During the meeting, Ross Renew, MD, Mayo Clinic, Jacksonville, Florida presented a poster entitled, *"Comparative Investigation of Acceleromyography-based IntelliVue NMT and Electromyography-based TetraGraph Quantitative Neuromuscular Monitors: a pilot study."*

The pilot study compared the TetraGraph, with Philips IntelliVue NMT Acceleromyography-based Monitor. In this pilot study, the EMG-based TOF measurements were more consistent compared to the AMG-based measurements. Though AMG proved more sensitive in detecting lower levels of neuromuscular blockade, the overall reliability and ease of use of the new electromyography-based device was better.

For further information, please contact:

Lena Söderström, CEO

Tel: +46-708-16 39 12

[Lena.soderstrom@senzime.com](mailto:Lena.soderstrom@senzime.com)

Catrin Molund, Marketing & Business Dev Director

Tel: +46-708-11 69 11

[Catrin.molund@senzime.com](mailto:Catrin.molund@senzime.com)

### TO THE EDITORS

#### About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. [www.senzime.com](http://www.senzime.com)